Skip to content Skip to footer
Subscribe Now
Takeda
News

Takeda Reports EMA Approval for Additional SC Administration Option of Takhzyro (lanadelumab) for Patients aged ≥12 with Recurrent HAE

Shots:Takeda reported the EMA's approval of an additional 2 mL pre-filled pen option for Takhzyro (lanadelumab) for patients aged ≥12 with Recurrent hereditary angioedema (HAE) Currently Takhzyro is approved in 150 mg and 300 mg pre-filled syringes and 300 mg vial. The new approval is for a 300 mg pre-filled pen (2 mL…
February 25, 2025

Read more

Viewpoints_Salom Juethner
VIEWPOINTS

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal AllergyShots:The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 2021

Read more